RESUMO
This study sought to perform clinical and imaging assessments of the DESolveBioresorbable Coronary Scaffold (BCS).Background BCS, which is drug eluting, may have potential advantages compared with conventionalmetallic drug-eluting stents. The DESolve system, designed to provide vessel support and neointimalsuppression, combines a poly-L-lactic acidbased scaffold with the antiproliferative myolimus.Methods The DESolve First-in-Man (A NON-RANDOMIZED, CONSECUTIVE ENROLLMENT EVALUATIONOF THE DESolve MYOLIMUS ELUTING BIORESORBABLE CORONARY STENT IN THE TREATMENT OFPATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS) trial was a prospective multicenterstudy enrolling 16 patients eligible for treatment. The principal safety endpoint was a composite ofcardiac death, myocardial infarction, and clinically indicated target lesion revascularization. Theprincipal imaging endpoint was in-scaffold late lumen loss (LLL) assessed by quantitative coronaryangiography (QCA) at 6 months. Intravascular ultrasound (IVUS) and optical coherence tomography(OCT) imaging was performed at baseline and 6 months; multislice computed tomography (MSCT) wasperformed at 12 months.Results Acute procedural success was achieved in 15 of 15 patients receiving a study scaffold. At12 months, there was no scaffold thrombosis and no major adverse cardiac events directly attributableto the scaffold. At 6 months, in-scaffold LLL (by QCA) was 0.19 0.19 mm; neointimal volume (by IVUS)was 7.19 3.56%, with no evidence of scaffold recoil or late malapposition. Findings were confirmedwith OCT and showed uniform, thin neointimal coverage (0.12 0.04 mm). At 12 months, MSCTdemonstrated excellent vessel patency.
